Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors
Top Cited Papers
- 5 February 2015
- journal article
- Published by American Society of Hematology in Blood
- Vol. 125 (6), 901-906
- https://doi.org/10.1182/blood-2014-09-594432
Abstract
Vascular safety is an emerging issue in patients with chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitors (TKIs). Whereas imatinib exhibits a well-documented and favorable long-term safety profile without obvious accumulation of vascular events, several types of vascular adverse events (VAEs) have been described in patients receiving second- or third-generation BCR/ABL1 TKIs. Such VAEs include pulmonary hypertension in patients treated with dasatinib, peripheral arterial occlusive disease and other arterial disorders in patients receiving nilotinib, and venous and arterial vascular occlusive events during ponatinib. Although each TKI interacts with a unique profile of molecular targets and has been associated with a unique pattern of adverse events, the mechanisms of drug-induced vasculopathy are not well understood. Here, recent data and concepts around VAEs in TKI-treated patients with CML are discussed, with special reference to potential mechanisms, event management, and strategies aimed at avoiding occurrence of such events in long-term treated patients.Keywords
This publication has 65 references indexed in Scilit:
- Resistance to Tyrosine Kinase Inhibition Therapy for Chronic Myelogenous Leukemia: A Clinical Perspective and Emerging Treatment OptionsClinical Lymphoma Myeloma and Leukemia, 2013
- Mechanism of impaired glucose metabolism during nilotinib therapy in patients with chronic myelogenous leukemiaHaematologica, 2013
- Ponatinib in Refractory Philadelphia Chromosome–Positive LeukemiasNew England Journal of Medicine, 2012
- Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-upLeukemia, 2012
- Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinibHaematologica, 2011
- Pleural and pericardial effusions in chronic myeloid leukemia patients receiving low-dose dasatinib therapyHaematologica, 2011
- Second line BCR/ABK TKI-associated severe adverse events:preferential occurrence in patients with comorbiditiesHaematologica, 2011
- Extensive pleural and pericardial effusion in chronic myeloid leukemia during treatment with dasatinib at 100 mg or 50 mg dailyHaematologica, 2010
- Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitorsNature Biotechnology, 2007
- Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid LeukemiaNew England Journal of Medicine, 2006